ST6GAL2 and central nervous system cancer: While these pathways are known to play critical roles in brain tumors, the levels, or ability, of ST6GAL1, ST6GAL2, or α2,6 sialylation to modulate BTIC signaling or maintenance to increase glioma growth has not been investigated.